Cytogenix (fka CYGX)

[Paulness]

nw-La , stop looking for third hand hearsay and read what really happened at the Spain conference .

http://cytogenix.com/en_us/Investors/DNAVaccine2007.ppt

May 2007

Dear Shareholders:

Dr. Yin Chen and I attended the 2007 DNA Vaccine Meeting in Malaga Spain. The program is provided at www.meetingsmanagement.com/dna_2007. Dr. Chen presented a paper entitled, "Production of DNA vaccines using a novel synDNA™ technology." He described results of experiments CytoGenix has performed to test Genetic Immunization Studies with synDNA™ based DNA vaccines. Please download the full presentation (1.8 MB Powerpoint file). The tests he described were conducted using Mice, Rabbits and Primates and included:

Influenza DNA Vaccine (HA)

in collaboration with Dr. Frank Orson of Baylor College of Medicine

Avian Influenza Vaccine (H5N1)

in collaboration with Dr. Slobodan Paessler of the University of Texas Medical Branch at Galveston

HIV DNA Vaccine

gp160- licensed a HIV DNA construct from NIH

Gag-Pol-Env- in collaboration with Dr. D. Weiner (U Penn)

Smallpox DNA Vaccine (B5R, A27L, A4L)

in collaboration with Dr. D. Weiner (U Penn)

Hepatitis B Virus DNA Vaccine (S antigen)

corporate collaboration with Aldevron, LLC

He also described ongoing experiments with several other collaborating agencies:

Brucella abortus DNA Vaccine

collaboration with USDA

Ebola, Equine Encephalitis DNA Vaccines

collaboration with USAMRIID

Erythropoietin (Epo) expression construct

corporate collaboration

DNA VACCINES 2007 is the third in the series of these meetings and showed the remarkable progress of DNA vaccines for both prophylactic and therapeutic applications. The presentations provided convincing examples of the use of DNA as a means of vaccination offering potential benefits in protective and therapeutic efficacy, cross-strain applicability, development speed and manufacturing cost compared with conventional vaccines. There were numerous demonstrations of the effectiveness that DNA vaccines have in inducing killer T-cell responses which are an important ingredient in fighting infections.

I found the meeting remarkable for the breadth of applications presented, the advances made in clinical trials, especially in cancer therapeutics and the demonstration of improvements in efficacy induced by adjuvant processes such as electroporation. In addition to the opportunity to see the advances in the field, Dr Chen and I talked with a number of scientists who expressed interest in trying synDNA™ constructs and with representatives from other companies with whom we are cooperating or wish to cooperate.

Please review Dr. Chen's presentation.

Very truly yours,

Malcolm Skolnick